Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous

NCT07210671 · tracked via the Priya Life Science France tracker

Sponsor

Centre Hospitalier Universitaire, Amiens

Phase

Observational

Started

2025-11-10

Last updated

2026-04-14

Condition(s) studied

Superficial Vein ThrombosisCancerVenous Thrombosis

Study summary

Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient over 18 * Patient affiliated to a social security scheme * Patient who understands French * Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old. * Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery) Exclusion Criteria: * Patients under legal protection * Patients with concomitant pulmonary embolism * Patient with proximal or distal deep vein thrombosis * Patient treated with anticoagulant therapy for another indication * Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding. * Patient opposed to participation in research

Primary outcome measure(s)

risk (in %) of recurrence of VTE — at 3-month follow-up
risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.

Trial sites (1)

Facility	City	Region	Status
CHU Amiens	Amiens	France	Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy Recruiting

MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD Recruiting

Is Cap Assisted Endoscopy Useful in Acute Upper Gastrointestinal Bleeding ? Recruiting

Salivary Replication of BK Virus in Post-kidney Transplant Starting soon

Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock? Recruiting

Other trials for the same condition

TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation Recruiting

Population-based Cancer Observatory Recruiting

Physical Exercise During the Cancer Care Pathway Starting soon

STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers Recruiting

Effects of Oncological Treatment During Pregnancy on Mother and Child Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07210671 on ClinicalTrials.gov ↗ ← All trials in France